Phase I study of TS-1+irinotecan+cetuximab as the first-line therapy in patients with KRAS wild-type metastatic colorectal cancer
- Conditions
- metastatic colorectal cancer
- Registration Number
- JPRN-UMIN000010639
- Lead Sponsor
- Japan Clinical Cancer Research Organization
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 16
Not provided
1) Synchronous multiple malignancy or metachronous multiple malignancy within 5 years disease free interval. 2) Symptomatic brain metastases 3) Severe infectious disease. 4) Comorbidity or history of interstitial lung disease or pulmonary fibrosis. 5) Comorbidity or history of severe heart disease. 6) Sensory alteration or paresthesia interfering with function. 7) Large quantity of pleural, abdominal or cardiac effusion. 8) Severe comorbidity (renal failure, liver failure, hypertension, etc.) 9) Prior radiotherapy for primary or metastases tumors. 10) Men/Women who are unwilling to avoid pregnancy. Women who are pregnant or breastfeeding. Women with a positive pregnancy test. 11) Any other cases who are regarded as inadequate for sydy enrollment by investigators.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method